Online Calculators
HCC risk in chronic hepatitis B patients without antiviral treatment
HCC risk in chronic hepatitis B patients without antiviral treatment
HCC risk in chronic hepatitis B patients with antiviral treatment
HCC risk in patients with chronic liver diseases
CU-HCC score was developed based on mainly untreated chronic hepatitis B (CHB) patients in Hong Kong. It has been extensively validated in Asian CHB population.
LSM-HCC score was refined from CU-HCC and used liver stiffness measurement (LSM) to replace the presence of cirrhosis. It was externally validated in Korea, and in an independent multi-centre cohort in China.
PAGE-B score was the first HCC risk score developed for antiviral treated Caucasian CHB patients. It has been extensively validated in Asian CHB population.
Modified PAGE-B score was developed in Korean CHB patients to modify PAGE-B score for Asian CHB population. It has been extensively validated in Asian CHB population.
CAMD score was developed in CHB patients from Taiwan, and externally validated in Hong Kong and Korean CHB patients.
REAL-B score was developed in a multicentre cohort of CHB patients from the US and Asia-Pacific region. It was externally validated in an independent multi-centre cohort in China.
aMAP score was developed in a multicentre cohort of CHB patient in China. It was externally validated in multiple cohorts of patients with CHB, chronic hepatitis C, and non-viral hepatitis.
| Parameters | CU-HCC | LSM-HCC | PAGE-B | mPAGE-B | CAMD | REAL-B | aMAP |
|---|---|---|---|---|---|---|---|
| Age |  |
|
|
|
|
|
|
| Gender (M/F) | |
|
|
|
|
||
| Platelet | |
|
|
|
|
||
| Cirrhosis (y/n) | |
|
|
||||
| LSM | |
||||||
| Diabetes (y/n) | |
||||||
| Alcohol use (y/n) | |
||||||
| HBV DNA | |
|
|
||||
| Albumin | |
|
|
||||
| Total bilirubin | |
|
|
||||
| AFP | |
|
|
CU-HCC: Wong VW, Chan SL, Mo F, et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol. 2010;28:1660-5.
LSM-HCC: Wong GL, Chan HL, Wong CK, et al. Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B. J Hepatol. 2014;60:339-45.
PAGE-B: Papatheodoridis G, Dalekos G, Sypsa V, et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. J Hepatol. 2016;64:800-6.
mPAGE-B: Kim JH, Kim YD, Lee M, et al. Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy. J Hepatol. 2018;69:1066-1073.
CAMD: Hsu YC, Yip TC, Ho HJ, et al. Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B. J Hepatol. 2018;69:278-285.
REAL-B: Yang HI, Yeh ML, Wong GL, et al. Real-World Effectiveness From the Asia Pacific Rim Liver Consortium for HBV Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated With Oral Antiviral Therapy. J Infect Dis. 2020;221:389-399.
aMAP: Fan R, Papatheodoridis G, Sun J, et al. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. J Hepatol. 2020;73:1368-1378.